TXNIP targeting has provided considerable and unique therapeutic opportunities concerning T1DM, T2DM, and the prevention of their long-term complications by improving insulin secretion and sensitivity along with β-cell function and integrity. The gene discussed is INS; the disease is type 2 diabetes mellitus.